CaseCare360: Enhancing ASCVD Care Through Immersive Clinical Decision-Making

PROGRAM OVERVIEW:
Case Care 360: Enhancing ASCVD Care Through Immersive Clinical Decision-Making

Start Activity

ACTIVITY TYPE
Enduring Internet

NLA ID:
2025026

ACTIVITY DATES
Release Date: October 15, 2025
Expiration Date: October 14, 2026

FEE INFORMATION
There is no cost associated with this activity.

TARGET AUDIENCE
The intended audience for the activity is primary care physicians involved in the management of patients with ASCVD.

LEARNING OBJECTIVES
At the end of this activity, all participants should be able to:

• Identify the long-term impact of elevated LDL-C on the pathophysiology of ASCVD.
• Integrate current guideline recommendations for LDL-C screening in patients who have experienced an ASCVD-related event.
• Apply the latest clinical evidence for non-statin therapies when managing patients who require additional LDL-C lowering or are statin intolerant.
• Employ shared decision-making strategies to improve adherence, address treatment barriers, and enhance long-term LDL-C management in patients with ASCVD.

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacist Accreditation Statement

Universal Activity Number Application UAN JA0007192-0000-25-023-H01-P (Application)
This Activity has been approved for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 1.25 contact hours.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit.  A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is October 14, 2026.  

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

*IMPORTANT* Pharmacists MUST request credit before October 14, 2026. Credit requested after this date will be subject to a fee by the accreditation board.

 

COMMERCIAL SUPPORT
This program is supported by an independent educational grant from Novartis Pharmaceuticals.

DISCLOSURE INFORMATION

FACULTY, PLANNERS & REVIEWERS

Peter P. Toth, MD, PhD
Consultant: Novartis, Merck
Speaker: Amgen

Heather Johnson, MD, MS, MMM, FAHA, FACC, FASPC
Consultant: Amgen, Medtronic, Novartis, Esperion
Speaker: Esperion

NLA staff have no relevant financial information to disclose.

NLA CME Committee Reviewers:

Scott Webster Shurmur, MD, FNLA, Vice-Chair
Consultant: Akcea

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.